Archbold Brian David sold $225K of MLAB

Archbold Brian David (SVP Operations) sold 2,516 shares of MESA LABORATORIES INC /CO/ (MLAB) at $89.50 ($0.23M total) on 2026-06-22.

Original reporting
SEC EDGAR · Archbold Brian David
Published Jun 23, 2026, 5:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 23, 2026, 5:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MLAB
Neutral
medium confidence
Mentioned
$MLAB
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MLABNeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price, and post-transaction holdings; it does not include any operational or financial update.

02

Market read

Traders may monitor for follow-on insider activity, but this single sale alone is unlikely to change valuation materially.

03

What to watch

Insider sales are more informative when aggregated over time (multiple officers, repeated sells) or when accompanied by other disclosures (earnings misses, guidance cuts, litigation).

Relevance 4/10Novelty 5/10Timing: Filed 2026-06-23; sale executed 2026-06-22.

Background

The article is an SEC Form 4 insider transaction disclosure for MESA LABORATORIES INC (MLAB).

Company-level read

Ticker impact

$MLABNeutralMedium confidence
Context

SEC Form 4 shows MESA LABORATORIES SVP Operations Archbold sold 2,516 shares at $89.5020 on 2026-06-22.

Expected impact

Limited near-term impact; any effect is likely short-lived unless repeated or paired with other negative disclosures.

Evidence & confidence

The filing is a disclosed sale (not a buy), but it provides no new company fundamentals, guidance, or regulatory/contract event.

Market effects

No sector read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

The sale may be driven by diversification, taxes, or pre-existing compensation plans rather than a bearish view; the article notes no 10b5-1 plan but that still doesn’t imply negative fundamentals.

Key entities

  • MLAB

    MESA LABORATORIES INC /CO/; subject of the Form 4 insider sale disclosure.

  • Archbold Brian David

    SVP Operations who sold 2,516 shares at $89.5020 on 2026-06-22.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MLABMedAI 8/10

Mesa Laboratories Inc (MLAB) Q2 2027 Earnings Call Highlights: Margin Expansion

Mesa Laboratories (MLAB) reported Q2 2027 earnings, highlighting margin expansion and strategic shifts. CEO Siddhartha Kadia discussed clinical genomics restructuring, aiming for profitability with a focus on pharmacogenomics and oncology. SDC grew 14.6% organically, while BPD saw an 8.2% decline due to timing issues. The company announced a $9.3 million savings plan, with $4.3 million reinvested. Full-year guidance is $250M-$255M revenue and $66M-$68M adjusted EBITDA.

$MLABMed

Mesa Labs (MLAB) Q2 2027 Earnings Call Transcript

Mesa Labs (MLAB) reported Q2 2027 earnings, highlighting 2.6% organic revenue growth, with Sterilization and Disinfection Control (SDC) up 14.6% and Calibration Solutions up 3.5%. Biopharmaceutical Development saw an 8.2% decline due to timing issues. The company announced cost-cutting measures in Clinical Genomics, reduced net leverage to 1.75x, and provided full-year guidance with revenues expected to grow 5-8%. A $40M share repurchase program was authorized.

$MLABHigh

Mesa Labs Revenue Rises 2.6%; Issues FY2027 Guidance

Mesa Labs reported Q2 FY2027 revenue of $62.3M, up 2.6% YoY, with net income of $4.3M. Adjusted EBITDA rose 21.1% to $17.3M. The company issued FY2027 guidance, expecting revenue of $250M-$255M and adjusted EBITDA of $66M-$68M. Mesa also announced a $40M share repurchase program.

$MLABHighAI 8/10

Mesa Labs Announces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance

MESA LABORATORIES INC /CO/ (MLAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mesa Labs Announces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance Lakewood, Colorado , November 9, 2026 – Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of critical quality